Gujarat Themis Biosyn Limited will hold its board meeting on September 1, 2026, to consider raising capital through a preferential issue of equity shares and convertible warrants.

The company disclosed the agenda in a filing with stock exchanges, citing compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The proposed fundraising is subject to shareholder approval and regulatory clearances under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013.

Trading Window Closure

Pursuant to the company’s Code of Conduct for Monitoring and Prevention of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons and their immediate relatives remains closed. This restriction continues until 48 hours after the announcement of the meeting’s outcome.

What the Numbers Show

The move signals Gujarat Themis Biosyn’s intent to strengthen its capital base through private placement rather than public issuance. The inclusion of convertible warrants alongside equity shares suggests a structured approach to balancing immediate liquidity needs with potential future dilution for investors.

Gujarat Themis Biosyn has set the floor price for its qualified institutional placement (QIP) at ₹372.57 per equity share. The Board of Directors approved this pricing during a meeting held on August 25, 2026, following shareholder clearance earlier in the month.

The floor price was determined based on the pricing formula prescribed under Regulation 176(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The relevant date for this calculation was August 25, 2026. Under the same regulations and the special resolution passed by shareholders on August 22, 2026, the company retains the discretion to offer a discount of up to 5% on this floor price.

Shareholder Approval Context

The QIP proceeds follow the near-unanimous support received from shareholders via postal ballot, which concluded on August 22, 2026. Voting was conducted through remote e-voting on the CDSL platform from July 24 to August 22, 2026. CS Ketan R. Shirwadkar of KRS AND CO. scrutinized the process.

Total votes polled amounted to 77.9 million out of 109.0 million outstanding shares, representing a 71.46% participation rate. Promoter and promoter group shareholders voted unanimously in favor, casting 74.0 million votes.

Trading Window Closure

In compliance with the company’s Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons, the trading window for dealing in Gujarat Themis Biosyn securities is closed. This restriction applies from August 25, 2026, until 48 hours after the determination of the final issue price. All 'Designated Persons' as defined in the Code are subject to this ban.

The Board also approved the preliminary placement document dated August 25, 2026, and the draft application form. These documents have been filed with the National Stock Exchange of India Limited and BSE Limited.